=> d his

L32

3 S L19,L29-L31

```
(FILE 'HOME' ENTERED AT 06:23:56 ON 28 OCT 2004)
                SET COST OFF
     FILE 'HCAPLUS' ENTERED AT 06:27:06 ON 28 OCT 2004
L1
              2 S US20040127702/PN OR (US2003-666175# OR US2002-425596# OR US20
                E PEARLMAN B/AU
L2
             31 S E4,E7-E9
                E ANTOSZ F/AU
             16 S E3-E5
L3
            183 S ?EPLERENON?
L4
     FILE 'REGISTRY' ENTERED AT 06:28:49 ON 28 OCT 2004
L5
             1 S 107724-20-9
     FILE 'HCAPLUS' ENTERED AT 06:29:31 ON 28 OCT 2004
                SET SMARTSELECT ON
            SEL L1 1- RN :
                              100 TERMS
L6
                SET SMARTSELECT OFF
     FILE 'REGISTRY' ENTERED AT 06:29:31 ON 28 OCT 2004
            100 S L6
Ь7
             27 S L7 AND OC4-C5-C6-C6-C6/ES
^{\text{L8}}
L9
              6 S L8 AND OC4/ES
              1 S L9 AND C27H32O4
L10
                E C27H32O4/MF
              1 S E3 AND OC4-C5-C6-C6-C6/ES AND OC4/ES
L11
              1 S L10, L11
L12
                SEL RN
              0 S E1/CRN
L13
     FILE 'HCAOLD' ENTERED AT 06:32:59 ON 28 OCT 2004
              0 S L12
L14
     FILE 'USPATFULL, USPAT2' ENTERED AT 06:33:00 ON 28 OCT 2004
              1 S L12
L15
     FILE 'HCAPLUS' ENTERED AT 06:33:01 ON 28 OCT 2004
L16
              3 S L12
L17
              1 S L16 AND L1-L3
L18
              2 S L16 AND (PHARMACIA? OR UPJOHN?)/PA,CS
              3 S L16-L18
L19
     FILE 'REGISTRY' ENTERED AT 06:37:28 ON 28 OCT 2004
L20
                STR
L21
              0 S L20
L22
                STR L20
L23
              7 S L22
L24
           2101 S L22 FUL
                SAV TEMP L24 QAZI666/A
L25
             45 S L20 FUL SUB=L24
                SAV TEMP L25 QAZI666A/A
L26
                STR L20
L27
             12 S L26 FUL SUB=L25
                SAV L27 TEMP QAZI666B/A
L28
          11 S L27 NOT L12
     FILE 'HCAPLUS' ENTERED AT 06:40:24 ON 28 OCT 2004
L29
              2 S L28
L30
              1 S L29 AND L1-L3
L31
              1 S L29 AND (PHARMACIA? OR UPJOHN?)/PA,CS
```

FILE 'USPATFULL, USPAT2' ENTERED AT 06:40:50 ON 28 OCT 2004

L33 1 S L28 L34 1 S L15,L33

=> fil reg

FILE 'REGISTRY' ENTERED AT 06:41:14 ON 28 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 OCT 2004 HIGHEST RN 769912-90-5 DICTIONARY FILE UPDATES: 26 OCT 2004 HIGHEST RN 769912-90-5


TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

=> d sta que 127 L20 STR



NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE L22 STR

NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE


L24 2101

2101 SEA FILE=REGISTRY SSS FUL L22

L25 45 SEA FILE=REGISTRY SUB=L24 SSS FUL L20

L26

STR



NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 28

STEREO ATTRIBUTES: NONE

1.27

12 SEA FILE=REGISTRY SUB=L25 SSS FUL L26

100.0% PROCESSED 13 ITERATIONS SEARCH TIME: 00.00.01

12 ANSWERS

=> d ide can 112

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN **610785-40-5** REGISTRY

CN Pregna-4,9(11)-diene-21-carboxylic acid, 17-hydroxy-7-(5-methyl-2-furanyl)-3-oxo-, γ -lactone, $(7\alpha,17\alpha)$ - (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C27 H32 O4


SR CA

LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:423864

REFERENCE 2: 139:307925

=> d ide can tot 128

L28 ANSWER 1 OF 11 REGISTRY COPYRIGHT 2004 ACS on STN

RN 690958-98-6 REGISTRY

CN Pregn-5-ene-21-carboxylic acid, 11,17-dihydroxy-7-(5-methyl-2-furanyl)-3-oxo-, γ -lactone, $(7\alpha,11\alpha,17\alpha)$ - (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C27 H34 O5

SR CA

LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

DT.CA CAplus document type: Patent

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 1 REFERENCES IN FILE CA (1907 TO DATE)
- 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:423864

L28 ANSWER 2 OF 11 REGISTRY COPYRIGHT 2004 ACS on STN

RN 690958-89-5 REGISTRY

CN Spiro[androst-5-ene-17,2'(3'H)-furan]-3-one, 4',5'-dihydro-5',11-dihydroxy-7-(5-methyl-2-furanyl)-, $(7\alpha,11\alpha,17\beta)$ - (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C27 H36 O5

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 1 REFERENCES IN FILE CA (1907 TO DATE)
- 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:423864

L28 ANSWER 3 OF 11 REGISTRY COPYRIGHT 2004 ACS on STN

RN 690958-83-9 REGISTRY

CN Pregn-5-ene-21-carboxylic acid, 3,11,17-trihydroxy-7-(5-methyl-2-furanyl)-, γ -lactone, (3 β ,7 α ,11 α ,17 α)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C27 H36 O5

SR CA

LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:423864

L28 ANSWER 4 OF 11 REGISTRY COPYRIGHT 2004 ACS on STN

RN 690958-80-6 REGISTRY

CN Spiro[androst-5-ene-17,2'(5'H)-furan]-5'-one, 3,11-bis(acetyloxy)-3',4'-dihydro-7-(5-methyl-2-furanyl)-, $(3\beta,7\alpha,11\alpha,17\beta)$ - (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C31 H40 O7

SR CA

LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:423864

L28 ANSWER 5 OF 11 REGISTRY COPYRIGHT 2004 ACS on STN

RN 690958-45-3 REGISTRY

CN Spiro[androst-5-ene-17,2'(3'H)-furan]-3,5',11-triol, 4',5'-dihydro-7-(5-methyl-2-furanyl)-, (3β,7α,11α,17β)- (9CI) (CA
INDEX NAME)

FS STEREOSEARCH

MF C27 H38 O5


SR CA

LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:423864

L28 ANSWER 6 OF 11 REGISTRY COPYRIGHT 2004 ACS on STN

RN 610785-54-1 REGISTRY

CN Pregn-4-ene-21-carboxylic acid, 11,17-dihydroxy-7-(4-methyl-2-furanyl)-3-oxo-, γ -lactone, $(7\alpha,11\alpha,17\alpha)$ - (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C27 H34 O5

SR CA

LC STN Files: CA, CAPLUS, CASREACT

DT.CA CAplus document type: Patent

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:307925

L28 ANSWER 7 OF 11 REGISTRY COPYRIGHT 2004 ACS on STN

RN 610785-53-0 REGISTRY

CN Pregn-4-ene-21-carboxylic acid, 7-(4-bromo-2-furanyl)-11,17-dihydroxy-3-oxo-, γ -lactone, $(7\alpha,11\alpha,17\alpha)$ - (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C26 H31 Br O5

SR CA

LC STN Files: CA, CAPLUS, CASREACT

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:307925

L28 ANSWER 8 OF 11 REGISTRY COPYRIGHT 2004 ACS on STN

RN 610785-52-9 REGISTRY

CN Pregn-4-ene-21-carboxylic acid, 7-[5-(1,1-dimethylethyl)-2-furanyl]-11,17-dihydroxy-3-oxo-, γ -lactone, $(7\alpha,11\alpha,17\alpha)$ - (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C30 H40 O5


SR CA

LC STN Files: CA, CAPLUS, CASREACT

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:307925

L28 ANSWER 9 OF 11 REGISTRY COPYRIGHT 2004 ACS on STN

RN 610785-51-8 REGISTRY

CN Pregna-4,9(11)-diene-21-carboxylic acid, 7-[5-(1,1-dimethylethyl)-2-furanyl]-17-hydroxy-3-oxo-, γ -lactone, (7 α ,17 α)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C30 H38 O4

SR CA

LC STN Files: CA, CAPLUS, CASREACT

DT.CA CAplus document type: Patent

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:307925

L28 ANSWER 10 OF 11 REGISTRY COPYRIGHT 2004 ACS on STN

RN 610785-48-3 REGISTRY

CN Pregn-4-ene-21-carboxylic acid, 9,11-epoxy-17-hydroxy-7-(5-methyl-2-furanyl)-3-oxo-, γ -lactone, $(7\alpha,11\alpha,17\alpha)$ - (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C27 H32 O5

SR CA

LC STN Files: CA, CAPLUS, CASREACT

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:307925

L28 ANSWER 11 OF 11 REGISTRY COPYRIGHT 2004 ACS on STN

RN 610785-47-2 REGISTRY

CN Pregn-4-ene-21-carboxylic acid, 11,17-dihydroxy-7-(5-methyl-2-furanyl)-3-oxo-, γ -lactone, $(7\alpha,11\alpha,17\alpha)$ - (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C27 H34 O5


SR CA

LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:423864

REFERENCE 2: 139:307925

=> fil hcaplus FILE 'HCAPLUS' ENTERED AT 06:41:48 ON 28 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Oct 2004 VOL 141 ISS 18 FILE LAST UPDATED: 27 Oct 2004 (20041027/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d 132 all hitstr tot

```
L32 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
```

AN 2004:817907 HCAPLUS

Entered STN: 07 Oct 2004

- Preparation of spirosteroids from 17-alkenyl or 17-alkynyl substrate via carbonylation, hydrogenation, dehydrogenation, furylation and other transformations
- Franczyk, Thaddeus S., II; Wagner, Grace M. TN
- Pharmacia Corporation, USA
- PCT Int. Appl., 177 pp. SO

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07J

CC 32-1 (Steroids)

FAN CNT 1

	ran.	CMI	Τ.																
PATENT NO.						KIND DATE			APPLICATION NO.						DATE				
	PI	WO 2004085458					A2 200410			1007	WO 2004-US8629						20040322		
			W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
				CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
				GΕ,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	ΚZ,	LC,
				LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,
				NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
																		ZM,	
			RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,
				BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,
			4	ES,	FI,	FR,	GB,	GR,	HU,	IE,	IT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,
																		NE,	-
				TD,	TG											•	•	•	·
PRAI US 2003-456716P				P		2003	0321												
	CLAS	S																	

CLASS PATENT FAMILY CLASSIFICATION CODES

PATENT NO.

WO 2004085458 ICM C07J

Ι

AB Steroids such as I (R1, R2, R3 = H, halo, haloalkyl, OH, alkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxycarbonyl, CN, aryloxy; A-A, B-B, D-D, and G-J = substituted or unsubstituted double or single bond with R groups similar to those for R1, R2, R3 in the substituted case) comprising a 17-spirolactone or corresponding open lactone structure is obtained by carbonylation of a 17-alkenyl or 17-alkynyl substrate. A 17-alkenyl intermediate may be prepared by semi-hydrogenation of a 17-alkynyl group. Multiple reaction schemes are disclosed for preparation of a 3-keto-9,11-epoxy-17-spirolactone steroid such as eplerenone. Novel intermediates are also disclosed, as well as steps for forming such novel intermediates, or converting them to further intermediates or products, by semi-hydrogenation, carbonylation, 6,7-dehydrogenation, furylation or other transformations or combinations thereof.

ST spirolactone steroid eplerenone prepn; hydrogenation carbonylation dehydrogenation furylation spirolactone steroid prepn

IT Carbonylation Dehydrogenation

Hydrogenation

(preparation of spirolactone steroid derivs. from 17-alkenyl or 17 alkynyl steroids via carbonylation, semi-hydrogenation, dehydrogenation, furylation and other transformations)

IT Steroids

IT

IT

IT

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(spiro; preparation of spirolactone steroid derivs. from 17-alkenyl or 17 alkynyl steroids via carbonylation, semi-hydrogenation, dehydrogenation, furylation and other transformations)

192704-66-8P 610269-44-8P 610269-45-9P 610269-50-6P 610269-51-7P 769146-02-3P 769146-04-5P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of spirolactone steroid derivs. from 17-alkenyl or 17 alkynyl steroids via carbonylation, semi-hydrogenation, dehydrogenation,

furylation and other transformations)
41850-21-9P 95716-71-5P 107724-20-9P, Eplerenone 610785-40-5P

769146-08**-**9P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation) (preparation of spirolactone steroid derivs. from 17-alkenyl or 17 alkynyl steroids via carbonylation, semi-hydrogenation, dehydrogenation, furylation and other transformations)

434-03-7, Ethisterone 534-22-5 28319-72-4 95716-70-4 769146-05-6 RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of spirolactone steroid derivs. from 17-alkenyl or 17 alkynyl steroids via carbonylation, semi-hydrogenation, dehydrogenation, furylation and other transformations)

IT 610785-40-5P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of spirolactone steroid derivs. from 17-alkenyl or 17 alkynyl steroids via carbonylation, semi-hydrogenation, dehydrogenation, furylation and other transformations)

RN 610785-40-5 HCAPLUS

CN Pregna-4,9(11)-diene-21-carboxylic acid, 17-hydroxy-7-(5-methyl-2-furanyl)-3-oxo-, γ -lactone, $(7\alpha,17\alpha)$ - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

```
L32 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
```

AN 2004:414628 HCAPLUS

DN 140:423864

ED Entered STN: 21 May 2004

TI Processes for preparing C-7 substituted steroids from 5-androsten-3 β -ol-17-one

IN Wuts, Peter Guillaume Marie

PA USA

SO U.S. Pat. Appl. Publ., 23 pp.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K031-58

ICS C07J043-00; C07J021-00; C07J017-00

Ρ

NCL 514173000; 514176000; 514178000; 540041000; 540107000; 540114000

CC 32-4 (Steroids)

PRAI US` 2002-424488P

Section cross-reference(s): 16

FAN.CNT 1

Truv.	PATENT NO.							DATE		i	APPLICATION NO.						DATE			
	I US 2004097475																			
PΙ				A1		20040520		US 2003-392945						20030321						
	WO 2004043986				A1		20040527		WO 2003-US7284						20030321					
		W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,		
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,		
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,		
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,		
			PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,		
		*	UA,	ŪĠ,	US,	UΖ,	VC,	VN,	ΥU,	ZA,	ZM,	ZW,	AM,	ΑZ,	BY,	KG,	ΚZ,	MD,		
			RU,	TJ,	\mathbf{TM}												*			
		RW:	GH,	GM,	KE,	LS,	MW,	ΜZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	BG,		
			CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,	MC,		
			NL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,		
			GW,	ML,	MR,	ΝE,	SN,	TD,	TG											

20021107

```
CLASS
```

GΙ

$$R^{3}$$
 Me
 H
 R^{17}
 R^{18}
 R^{10}
 $R^$

The present invention discloses a process for the transformation of 5-androsten-3 β -ol-17-one (I) to C-7 substituted steroids, such as II [R1 = H, COR2; R2 = alkyl, alkoxy; R3 = H, OR1; R17R18 = O, lactone; Y = CN, CH2CH:CH2, 5-(C1-6-alkyl)-2-furyl, 1-(C1-6-alkyl)-2-pyrrolyl, CHR4C(O)aryl, CHR4C(O)alkyl, CHR4C(O)X-aryl, CHR4C(O)X-alkyl; R4 = alkyl, aryl; X = O, S, dashed bond = single bond or double bond]. Thus, bioconversion of I to 5-androsten-3 β ,7 β -diol-17-one (III) was performed using a submerged culture of Diplodia gossypina ATCC 20571. III was subsequently converted to 5-androsten-3 β ,7 β ,11 α -triol-17-one (IV) using a submerged culture of Aspergillus ochraceus ATCC 18500. IV can also be obtained from II using a submerged culture of Absidia coerulea ATCC 6647. These intermediates are useful in the preparation of eplerenone (V).

ST carboxysteroid eplerenone prepn androstenol deriv hydroxylation androstenone; hydroxyandrostenone dihydroxyandrostenone trihydroxyandrostenone prepn

IT Aspergillus ochraceus

(ATCC 18500; for 11α -hydroxylation of 5-androsten-3 β ,7 β -diol-17-one in preparation of C-7 substituted steroids from 5-androsten-3 β -ol-17-one)

IT Diplodia gossypina

(ATCC 20571; for 7 β -hydroxylation of 5-androsten-3 β -ol-17-one in preparation of C-7 substituted steroids from 5-androsten-3 β -ol-17-one)

IT Absidia coerulea

(ATCC 6647; for 7 β ,11 α -dihydroxylation of 5-androsten-3 β -ol-17-one in preparation of C-7 substituted steroids from 5-androsten-3 β -ol-17-one)

IT Hydroxylation

(biol.; during preparation of C-7 substituted steroids from 5-androsten-3 β -ol-17-one)

IT Lewis acids

RL: CAT (Catalyst use); USES (Uses)
 (catalyst; during preparation of C-7 substituted steroids from
5-androsten-3β-ol-17-one)

IT Bromination
Dehydration reaction
Ozonization

```
(during preparation of C-7 substituted steroids from 5-androsten-3β-ol-
        17-one)
     Isomerization
TT
        (of 4,5-double bond during preparation of C-7 substituted steroids from
        5-androsten-3β-ol-17-one)
IT
     Nucleophiles
        (preparation of C-7 substituted steroids from 5-androsten-3β-ol-17-one)
IT
     Steroids, preparation
     RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); IMF
     (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation);
     BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
        (preparation of C-7 substituted steroids from 5-androsten-3β-ol-17-one)
IT
     Sterols
     RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); RCT
     (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent)
        (preparation of C-7 substituted steroids from 5-androsten-3β-ol-17-one)
     Acylation
IT
     Esterification
     Hydroformylation
     Oxidation
     Silylation
        (stereoselective; during preparation of C-7 substituted steroids from
        5-androsten-3\beta-ol-17-one)
IT
     Allylation
        (stereoselective; preparation of C-7 substituted steroids from
        5-androsten-3\beta-ol-17-one)
IT
     537718-07-3P
     RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); RCT
     (Reactant); BIOL (Biological study); PREP (Preparation); RACT (Reactant or
     reagent)
        (preparation of C-7 substituted steroids from 5-androsten-3\beta-ol-17-one)
IT
     95716-70-4P
                  192704-56-6P 537718-14-2P 610785-40-5P
     610785-45-0P 610785-47-2P
                                 685877-48-9P
                                               685877-49-0P
     685877-50-3P
                   685877-51-4P
                                   690958-24-8P
                                                 690958-30-6P
                                                                 690958-38-4P
     690958-45-3P 690958-80-6P 690958-83-9P
                   690958-95-3P 690958-98-6P
     690958-89-5P
     RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); RCT
     (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent)
        (preparation of C-7 substituted steroids from 5-androsten-3β-ol-17-one)
TΤ
     107724-20-9P, Eplerenone
     RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); SPN
     (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
        (preparation of C-7 substituted steroids from 5-androsten-3β-ol-17-one)
ΙT
     192704-58-8P
    RL: BPN (Biosynthetic preparation); IMF (Industrial manufacture); RCT
     (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent)
        (preparation of C-7 substituted steroids from 5-androsten-3β-ol-17-one)
IT
     2487-48-1P
    RL: BPN (Biosynthetic preparation); RCT (Reactant); BIOL (Biological
     study); PREP (Preparation); RACT (Reactant or reagent)
        (preparation of C-7 substituted steroids from 5-androsten-3β-ol-17-one)
IT
     54761-04-5, Ytterbium triflate
                                    144026-79-9, Scandium triflate
    RL: CAT (Catalyst use); USES (Uses)
        (preparation of C-7 substituted steroids from 5-androsten-3\beta-ol-17-one)
IT
     690959-06-9P
                  690959-08-1P
                                 690959-11-6P
                                                 690959-13-8P
    RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
     (Preparation)
        (preparation of C-7 substituted steroids from 5-androsten-3β-ol-17-one)
IT
     53-43-0
              74-86-2, Acetylene, reactions 534-22-5, 2-Methylfuran
```

762-72-1, Allyltrimethylsilane 763-13-3 7677-24-9,

Trimethylsilylcyanide 40474-65-5 67576-47-0 86298-22-8 537718-13-1 RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of C-7 substituted steroids from 5-androsten-3β-ol-17-one)

144-62-7, Oxalic acid, reactions IT

RL: RGT (Reagent); RACT (Reactant or reagent)

(preparation of C-7 substituted steroids from 5-androsten-3β-ol-17-one)

IT 75-05-8, Acetonitrile, uses 75-09-2, Dichloromethane, uses

RL: NUU (Other use, unclassified); USES (Uses)

(solvent; preparation of C-7 substituted steroids from 5-androsten-3βol-17-one)

IT 610785-40-5P 610785-47-2P 690958-45-3P 690958-80-6P 690958-83-9P 690958-89-5P

690958-98-6P

RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of C-7 substituted steroids from 5-androsten-3 β -ol-17-one)

610785-40-5 HCAPLUS RN

CN Pregna-4,9(11)-diene-21-carboxylic acid, 17-hydroxy-7-(5-methyl-2-furanyl)-3-oxo-, γ -lactone, $(7\alpha, 17\alpha)$ - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN610785-47-2 HCAPLUS

CN Pregn-4-ene-21-carboxylic acid, 11,17-dihydroxy-7-(5-methyl-2-furanyl)-3oxo-, γ -lactone, $(7\alpha, 11\alpha, 17\alpha)$ - (9CI) (CA INDEX NAME)

CN Spiro[androst-5-ene-17,2'(3'H)-furan]-3,5',11-triol, 4',5'-dihydro-7-(5-methyl-2-furanyl)-, (3β,7α,11α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 690958-80-6 HCAPLUS

CN Spiro[androst-5-ene-17,2'(5'H)-furan]-5'-one, 3,11-bis(acetyloxy)-3',4'dihydro-7-(5-methyl-2-furanyl)-, (3β,7α,11α,17β)(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 690958-83-9 HCAPLUS

CN Pregn-5-ene-21-carboxylic acid, 3,11,17-trihydroxy-7-(5-methyl-2-furanyl)-, γ -lactone, (3 β ,7 α ,11 α ,17 α)- (9CI) (CA INDEX NAME)

RN 690958-89-5 HCAPLUS

CN Spiro[androst-5-ene-17,2'(3'H)-furan]-3-one, 4',5'-dihydro-5',11-dihydroxy-7-(5-methyl-2-furanyl)-, $(7\alpha,11\alpha,17\beta)$ - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 690958-98-6 HCAPLUS

CN Pregn-5-ene-21-carboxylic acid, 11,17-dihydroxy-7-(5-methyl-2-furanyl)-3-oxo-, γ -lactone, $(7\alpha,11\alpha,17\alpha)$ - (9CI) (CA INDEX NAME)

```
ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
L32
     2003:796726 HCAPLUS
AN
DN
     139:307925
ED
     Entered STN: 10 Oct 2003
TI
     Process to prepare eplerenone and its intermediates from
     Δ9-canrenone and other pregnanes
     Pearlman, Bruce Allen; Padilla, Amphlett Greq; Havens, Jeffrey
IN
     L.; Mackey, Sonja S.; Wu, Haifeng
     Pharmacia & Upjohn Company, USA
PA
SO
    PCT Int. Appl., 429 pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English
IC
     ICM C07J001-00
     32-5 (Steroids)
     Section cross-reference(s): 2, 63
     PATENT NO.
                         KIND
                                DATE
                                            APPLICATION NO.
                                                                   DATE
                         _ _ _ _
                                -----
                                            ______
                          A2
PΙ
     WO 2003082895
                                20031009
                                            WO 2003-US7793
                                                                   20030321 <--
     WO 2003082895
                          Α3
                                20040422
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ,
             MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
             NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
             GW, ML, MR, NE, SN, TD, TG
    US 2003232981
                                20031218
                                            US 2003-392833
                                                                   20030321 <--
                         Α1
    US 2004024202
                          A1
                                20040205
                                            US 2003-392857
                                                                   20030321 <--
    WO 2004037844
                          A1
                                20040506
                                            WO 2003-US29923
                                                                   20030919 <--
    WO 2004037844
                                20040610
                          C1
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
            NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    US 2004127702
                         A1
                                20040701
                                            US 2003-666175
                                                                   20030919 <--
PRAI US 2002-366784P
                          р
                                20020322
                          Ρ
                                20020919
     US 2002-411874P
                                          <--
    US 2002-425596P
                                20021112
                          Р
                                          <--
     US 2003-392833
                                20030321
                          A
CLASS
 PATENT NO.
                 CLASS
                        PATENT FAMILY CLASSIFICATION CODES
                 ____
                        ______
WO 2003082895
                 ICM
                        C07J001-00
    CASREACT 139:307925; MARPAT 139:307925
GΙ
```

qazi - 10 / 666175 Page 21 * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT * AB The present invention involves novel intermediates I [R9 = H, OH, O-PG, F; PG = SiMe3, SiEt3, Ac, CHO; R11 = :0, H2, α R11-1 β R11-2, R11-5R11-6; R11-1 = H, OR11-3; R11-2 = H, OR11-4; R11-3 = H, PG; R11-4 = H, PG; R11-5R9 = bond, R11-6 = H or R11-6R9 = bond, R11-5 = H; R11-7R9 = O; R11-8 = H; R17 = :0, α R17-1 β R17-2, α R17-3 β R17-4, $\alpha R17 - 5\beta R17 - 6$, $\alpha R17 - 7\beta R17 - 8$, OCH (OR17 - 9) CH2CH2, $\alpha R17-11\beta R17-12$; R17-1 = H, C.tplbond.CH, CN, C.tplbond.CCH2αR17-1-1, C.tplbond.CCH2O-PG, CH2CH2CO2-; R17-2 = OH; R17-3 = OH; R17-4 = COMe, COCH2OH, COCH2OC(:O)(CH2)0-3Me; R17-5R17-6 = α -CH2O- β ; R17-7R17-8 = α -OC(:0)CH2CH2- β ; R17-9 = H, C1-3-alky1; R17-11 = (CH2)1-2CH:CH2; R17-12 = OH; R17-1-1 = H, Si(R17-1-2)3; R17-1-2 = C1-4-alkyl, CH(OEt)Me, THP], including an 7α -substituted steroid, and various novel processes which are used to prepare known intermediates useful in the production of eplerenone, a pharmaceutical agent. Thus, pregnadienone spirolactone II was prepared from Δ9-canrenone (III) via conjugate addition of 2-methylfuran in MeNO2 containing BF3.OEt2, ring cleavage with dibromantin in aqueous THF containing KOAc, ozonolysis (03/02) in CH2Cl2/02(CHMe2)2 with Me2S quenching in CHCl3 and oxidation in CHCl3 with H2O2 in H2O containing KHCO3. steplerenone steroid prepn; hexahydronaphthalene ketal enol ether prepn ΤT Isomerization (cis-trans, of pregnenone maleates to fumarates; preparation of eplerenone and its intermediates from $\Delta 9$ -canrenone and other pregnanes) Addition reaction IT (conjugate, of furans to pregnenones; preparation of eplerenone and its intermediates from Δ9-canrenone and other pregnanes) TT Ethers, reactions RL: RCT (Reactant); RACT (Reactant or reagent) (enol, alkyl, reaction of, with a hydride abstractor; preparation of eplerenone and its intermediates from $\Delta 9$ -canrenone and other pregnanes) IT Oxidation, electrochemical (from alkyl enol ethers; preparation of eplerenone and its intermediates from $\Delta 9$ -canrenone and other pregnanes) ITAbstraction reaction (hydrogen, from alkyl enol ethers; preparation of eplerenone and its intermediates from $\Delta 9$ -canrenone and other pregnanes) IT Alcohols, reactions Glycols, reactions RL: RCT (Reactant); RACT (Reactant or reagent) (ketalization by, of $\Delta 3,5$ -dienol ether; preparation of eplerenone and its intermediates from $\Delta 9$ -canrenone and other pregnanes) IT Ozonization (of pregnenone maleates and fumarates; preparation of eplerenone and its intermediates from Δ9-canrenone and other pregnanes) IT Steroids, preparation RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (pregnanes; preparation of eplerenone and its intermediates from $\Delta 9$ -canrenone and other pregnanes) IT Ketals RL: SPN (Synthetic preparation); PREP (Preparation) (Δ4,6-; preparation of eplerenone and its intermediates from $\Delta 9$ -canrenone and other pregnanes) TT 534-22-5, 2-Methylfuran 930-27-8, 3-Methylfuran 2-(tert-Butyl)furan RL: RCT (Reactant); RACT (Reactant or reagent)

its intermediates from $\Delta 9$ -canrenone and other pregnanes) IT 22037-28-1P, 3-Bromofuran

and

(conjugate addition of, to pregnadienone derivs.; preparation of eplerenone

```
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (conjugate addition of, to pregnadienone derivs.; preparation of eplerenone
and
        its intermediates from \Delta 9-canrenone and other pregnanes)
IT
     95716-71-5, Δ9-Canrenone
                                192569-17-8, 11\alpha-Hydroxycanrenone
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (conjugate addition to, by methylfurans; preparation of eplerenone and its
        intermediates from \Delta 9-canrenone and other pregnanes)
IT
     192704-56-6, 11\alpha, 17\beta-Dihydroxypregn-4-en-3-one
     7\alpha,21-dicarboxylic acid \gamma-lactone methyl ester
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (dehydration of; preparation of eplerenone and its intermediates from
        Δ9-canrenone and other pregnanes)
IT
     67-68-5D, DMSO, o-iodoxybenzoic acid complex
                                                     75-91-2D, ruthenium
                           84-58-2, DDQ
     trichloride complex
                                           118-75-2, p-Chloranil, reactions
     341-02-6, Trityl fluoroborate 536-80-1, Iodosobenzene 546-67-8, Lead
                    993-02-2, Manganic acetate
     tetraacetate
                                                  1122-96-9D, 4-Methoxypyridine
     N-oxide, o-iodoxybenzoic acid complex 1184-78-7D, Trimethylamine
     N-oxide, o-iodoxybenzoic acid complex
                                              1313-13-9, Manganese dioxide,
                 1333-82-0D, Chromium trioxide, 2,5-dimethylpyrazole complex
     reactions
     2435-53-2, o-Chloranil
                              2712-78-9, Iodobenzene bistrifluoroacetate
     3240-34-4, Iodobenzene diacetate
                                         3375-31-3
                                                     7529-22-8D,
     N-Methylmorpholine N-oxide, o-iodoxybenzoic acid complex
                                                                  7782-68-5,
     Iodic acid (HIO3)
                         10049-08-8D, Ruthenium trichloride, tert-Bu
     hydroperoxide complex
                              10139-51-2, Ceric ammonium nitrate
                                                                    12029-98-0,
     Iodine pentoxide
                        14546-48-6, Manganese(III), reactions
                                                                  15158-12-0,
     Lead+4, reactions
                         16065-88-6, reactions
                                                  18540-29-9, reactions
     20492-50-6
                  22537-44-6, Ruthenium+8, reactions 23317-90-0, Manganese+7,
     reactions
                 64297-64-9, o-Iodoxybenzoic acid
     RL: RGT (Reagent); RACT (Reactant or reagent)
        (hydrogen abstraction by, in \delta4,6-steroid ketals; preparation of
        eplerenone and its intermediates from \Lambda 9-canrenone and other
        pregnanes)
IT
     107-21-1, Ethylene glycol, reactions
                                             126-30-7, Neopentyl glycol
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (ketalization by, of \Delta 3,5-dienol ether; preparation of eplerenone and
        its intermediates from \Delta 9-canrenone and other pregnanes)
IT
     192704-66-8
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (ketalization of; preparation of eplerenone and its intermediates from
        Δ9-canrenone and other pregnanes)
IT
     610785-46-1P
     RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
        (preparation and Baeyer-Villiger oxidation of, with peracetic acid;
preparation of
        eplerenone and its intermediates from \Delta 9-canrenone and other
        pregnanes)
IT
     610785-42-7P
     RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
     USES (Uses)
        (preparation and cis-trans isomerization of; preparation of eplerenone and
its
        intermediates from Δ9-canrenone and other pregnanes)
     610785-55-2P
TΤ
     RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
     study); PREP (Preparation); USES (Uses)
        (preparation and crystal structure of; preparation of eplerenone and its
        intermediates from \Delta 9-canrenone and other pregnanes)
IT
     610785-47-2P
```

```
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
     USES (Uses)
        (preparation and dehydration of; preparation of eplerenone and its
intermediates
        from \Delta 9-canrenone and other pregnanes)
ΙT
     95716-74-8P
     RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
        (preparation and esterification or lactone hydrolysis of; preparation of
        eplerenone and its intermediates from A9-canrenone and other
        pregnanes)
TΤ
     610785-44-9P
     RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
     USES (Uses)
        (preparation and intramol. conjugate addition of; preparation of eplerenone
and its
        intermediates from \Delta 9-canrenone and other pregnanes)
TT
     610785-45-0P
     RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
     USES (Uses)
        (preparation and ketalization of; preparation of eplerenone and its
intermediates
        from \Delta 9-canrenone and other pregnanes)
IT
     610785-57-4P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation and ozonolysis of; preparation of eplerenone and its
intermediates
        from \Delta 9-canrenone and other pregnanes)
     610785-41-6P
                    610785-43-8P
TT
     RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
     USES (Uses)
        (preparation and ozonolysis of; preparation of eplerenone and its
intermediates
        from \Delta 9-canrenone and other pregnanes)
     610785-50-7P
     RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
     study); PREP (Preparation); USES (Uses)
        (preparation and ozonolysis of; preparation of eplerenone and its
intermediates
        from \Delta 9-canrenone and other pregnanes)
     610785-56-3P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation and ozonolysis or reaction of, with hydrogen peroxide;
preparation
        of eplerenone and its intermediates from \Delta 9-canrenone and other
        pregnanes)
IT
     610785-40-5P
     RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
     USES (Uses)
        (preparation and ring cleavage of, with dibromantin; preparation of
eplerenone
        and its intermediates from \Delta 9-canrenone and other pregnanes)
TT
     107724-20-9P, Eplerenone
     RL: PNU (Preparation, unclassified); PREP (Preparation)
        (preparation of eplerenone and its intermediates from \Delta 9-canrenone and
```

other pregnanes)

IT 95717-00-3, 9α , 11α -Epoxycanrenone

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of eplerenone and its intermediates from $\Delta 9$ -canrenone and other pregnanes)

IT 611199-42-9, N-(1,1,2,2,3,3,3-Hexafluoropropyl)diethylamine

RL: RGT (Reagent); RACT (Reactant or reagent)

(preparation of eplerenone and its intermediates from $\Delta 9$ -canrenone and other pregnanes)

IT 95716-70-4P 209253-82-7P 610785-38-1P 610785-39-2P

610785-48-3P 610785-49-4P 610785-51-8P

610785-52-9P 610785-53-0P 610785-54-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of eplerenone and its intermediates from $\Delta 9$ -canrenone and other pregnanes)

IT 610785-47-2P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation and dehydration of; preparation of eplerenone and its intermediates $\ensuremath{\mathcal{C}}$

from $\Delta 9$ -canrenone and other pregnanes)

RN 610785-47-2 HCAPLUS

CN Pregn-4-ene-21-carboxylic acid, 11,17-dihydroxy-7-(5-methyl-2-furanyl)-3-oxo-, γ -lactone, $(7\alpha,11\alpha,17\alpha)$ - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 610785-40-5P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation and ring cleavage of, with dibromantin; preparation of eplerenone $\ensuremath{\mathsf{e}}$

and its intermediates from $\Delta 9$ -canrenone and other pregnanes)

RN 610785-40-5 HCAPLUS

CN Pregna-4,9(11)-diene-21-carboxylic acid, 17-hydroxy-7-(5-methyl-2-furanyl)-3-oxo-, γ -lactone, (7 α ,17 α)- (9CI) (CA INDEX NAME)

IT 610785-48-3P 610785-51-8P 610785-52-9P 610785-53-0P 610785-54-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of eplerenone and its intermediates from $\Delta 9$ -canrenone and other pregnanes)

RN 610785-48-3 HCAPLUS

CN Pregn-4-ene-21-carboxylic acid, 9,11-epoxy-17-hydroxy-7-(5-methyl-2-furanyl)-3-oxo-, γ -lactone, $(7\alpha,11\alpha,17\alpha)$ - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 610785-51-8 HCAPLUS

CN Pregna-4,9(11)-diene-21-carboxylic acid, 7-[5-(1,1-dimethylethyl)-2-furanyl]-17-hydroxy-3-oxo-, γ -lactone, $(7\alpha,17\alpha)$ - (9CI) (CA INDEX NAME)

RN 610785-52-9 HCAPLUS

CN Pregn-4-ene-21-carboxylic acid, 7-[5-(1,1-dimethylethyl)-2-furanyl]-11,17-dihydroxy-3-oxo-, γ -lactone, (7 α ,11 α ,17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 610785-53-0 HCAPLUS

CN Pregn-4-ene-21-carboxylic acid, 7-(4-bromo-2-furanyl)-11,17-dihydroxy-3-oxo-, γ -lactone, (7 α ,11 α ,17 α)- (9CI) (CA INDEX NAME)

RN610785-54-1 HCAPLUS

CNPregn-4-ene-21-carboxylic acid, 11,17-dihydroxy-7-(4-methyl-2-furanyl)-3oxo-, γ -lactone, $(7\alpha, 11\alpha, 17\alpha)$ - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil uspatall

FILE 'USPATFULL' ENTERED AT 06:42:07 ON 28 OCT 2004 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 06:42:07 ON 28 OCT 2004 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> => d 134 bib abs hitstr

ANSWER 1 OF 1 USPATFULL on STN L34

2004:127491 USPATFULL AN

TIProcesses for preparing C-7 substituted steroids

Wuts, Peter Guillaume Marie, Mattawan, MI, UNITED STATES IN 20040520

PΙ US 2004097475 Α1

ΑI US 2003-392945 20030321 (10) Α1

US 2002-424488P 20021107 (60) PRAI

DTUtility FS APPLICATION

LREP PHARMACIA & UPJOHN, 301 HENRIETTA ST, 0228-32-LAW, KALAMAZOO, MI, 49007

CLMN Number of Claims: 8 ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 975

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to processes for the preparation of novel 7-carboxy substituted steroid compounds of Formula I, ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 610785-40-5P 610785-47-2P 690958-45-3P

690958-80-6P 690958-83-9P 690958-89-5P 690958-98-6P

(preparation of C-7 substituted steroids from 5-androsten-3β-ol-17-one)

RN 610785-40-5 USPATFULL

CN Pregna-4,9(11)-diene-21-carboxylic acid, 17-hydroxy-7-(5-methyl-2-furanyl)-3-oxo-, γ -lactone, (7 α ,17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 610785-47-2 USPATFULL

CN Pregn-4-ene-21-carboxylic acid, 11,17-dihydroxy-7-(5-methyl-2-furanyl)-3-oxo-, γ -lactone, $(7\alpha,11\alpha,17\alpha)$ - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 690958-45-3 USPATFULL

CN Spiro[androst-5-ene-17,2'(3'H)-furan]-3,5',11-triol, 4',5'-dihydro-7-(5-methyl-2-furanyl)-, $(3\beta,7\alpha,11\alpha,17\beta)$ - (9CI) (CA

INDEX NAME)

Absolute stereochemistry.

RN 690958-80-6 USPATFULL

Absolute stereochemistry.


RN 690958-83-9 USPATFULL

CN Pregn-5-ene-21-carboxylic acid, 3,11,17-trihydroxy-7-(5-methyl-2-furanyl)-, γ -lactone, (3 β ,7 α ,11 α ,17 α)- (9CI) (CA INDEX NAME)

RN 690958-89-5 USPATFULL

CN Spiro[androst-5-ene-17,2'(3'H)-furan]-3-one, 4',5'-dihydro-5',11-dihydroxy-7-(5-methyl-2-furanyl)-, $(7\alpha,11\alpha,17\beta)$ - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690958-98-6 USPATFULL

CN Pregn-5-ene-21-carboxylic acid, 11,17-dihydroxy-7-(5-methyl-2-furanyl)-3-oxo-, γ -lactone, $(7\alpha,11\alpha,17\alpha)$ - (9CI) (CA INDEX NAME)

